Feasibility study of hyperthermic treatment by ASKIRF-8 for solid tumors

Feasibility study of hyperthermic treatment by ASKIRF-8 for solid tumors - Feasibility study of hyperthermic treatment

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000048984

Enrollment

Registered

2022-10-01

Start date

2022-04-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumors

Interventions

ASKIRF-8

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Solid tumor with histological proof. 2. Performance status (PS) 0 to 3

Exclusion criteria

Exclusion criteria: 1. Ophthalmological cancer and brain tumors 2. Hematological malignancies 3. Metal in around the treatment region

Design outcomes

Primary

Measure	Time frame
Completion rate of scheduled hyperthermic treatment	—

Secondary

Measure	Time frame
Incidence and grade of adverse reactions. 6-month and 1-year overall survival 6-month and 1-year relapse free survival	—

Countries

Japan

Contacts

Public ContactTakeshi Hara

Matsunami General Hospital Division of Hematology and Medical Oncology

haratake@muh.biglobe.ne.jp058-388-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026